neflamapimod-psp

Overview

flowchart TD
    PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
    PSP["PSP"] -->|"associated with"| Als["Als"]
    PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
    PSP["PSP"] -->|"expressed in"| neurons["neurons"]
    PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
    PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
    PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
    PSP["PSP"] -->|"regulates"| STX6["STX6"]
    PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
    PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
    PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
    PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
    PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
    PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
    style PSP fill:#4fc3f7,stroke:#333,color:#000

Nefamapimod (VX-745) is a selective small molecule inhibitor of p38 mitogen-activated protein kinase (MAPK) that was investigated for the treatment of progressive supranuclear palsy (PSP), specifically Richardson’s syndrome (PSP-RS). This Phase 2 clinical trial (NCT02444120) represented a novel therapeutic approach targeting the neuroinflammatory and tau pathological processes that underlie PSP

The selection of p38 MAPK as a therapeutic target in PSP reflects the growing recognition that neuroinflammation plays a critical role in neurodegenerative tauopathies. Unlike approaches that directly target tau protein through antibodies or antisense oligonucleotides, nefamapimod aims to modulate the upstream kinase pathways that contribute to tau phosphorylation, aggregation, and propagation. This mechanism-based strategy seeks to address the root causes of tau pathology rather than merely removing extracellular tau aggregates

PSP represents a particularly appropriate indication for p38 MAPK inhibition due to the prominent neuroinflammatory component of the disease. Post-mortem studies have demonstrated extensive microglial activation in PSP brains, and biomarker studies have shown elevated inflammatory markers in the cerebrospinal fluid of PSP patients. By targeting p38 MAPK, a central regulator of inflammatory responses in the central nervous system, nefamapimod aimed to reduce both neuroinflammation and the downstream consequences of inflammatory signaling on tau pathology

Trial Details

Scientific Background

The p38 MAPK Signaling Pathway

p38 mitogen-activated protein kinase (p38 MAPK) is a serine/threonine kinase that exists in four isoforms: p38α, p38β, p38γ, and p38δ. Of these, p38α is the predominant isoform expressed in the central nervous system and is the primary target of nefamapimod and other p38 MAPK inhibitors in development for neurological diseases^{1p38 MAPK isoforms in the brain2022 · Cell Mol Neurobiol · PMID 35006673Open reference}.

p38 MAPK Activation

p38 MAPK is activated by various cellular stresses and inflammatory stimuli:

1. Environmental Stress: UV radiation, oxidative stress, heat shock

2. Inflammatory Cytokines: IL-1β, TNF-α, and other pro-inflammatory mediators

3. Growth Factors: Some growth factor signaling cascades

4. Pathogen-Associated Molecular Patterns: Toll-like receptor activation

5. Cellular Damage: ATP, uric acid crystals, and damage-associated patterns

Downstream Targets

Once activated, p38 MAPK phosphorylates numerous downstream targets involved in:

Transcription Factors:

• ATF-2 (activating transcription factor-2)

• C/EBP (CCAAT/enhancer-binding protein)

• CREB (cAMP response element-binding protein)

• Elk-1 (ETS-domain containing protein)

Kinases:

• MSK1/2 (mitogen- and stress-activated kinase)

• MK2/3 (MAPK-activated protein kinase)

• PRAK (p38-regulated/activated protein kinase)

Cellular Proteins:

• Tau protein at multiple phosphorylation sites

• Cytoskeletal proteins

• Apoptotic regulators

p38 MAPK in Neurodegeneration

The p38 MAPK pathway is chronically activated in multiple neurodegenerative conditions, including Alzheimer’s disease, Parkinson’s disease, and tauopathies such as PSP^{2p38 MAPK in tauopathies2015 · J Neurochem · PMID 25645531Open reference}. This activation contributes to disease pathogenesis through several interconnected mechanisms.

Neuroinflammation

p38 MAPK is a master regulator of the inflammatory response in the brain^{3p38 MAPK and neuroinflammation2007 · Prog Neuropsychopharmacol Biol Psychiatry · PMID 17259054Open reference}:

Microglial Activation:

• p38 MAPK regulates microglial cytokine production

• Controls expression of inducible nitric oxide synthase (iNOS)

• Regulates cyclooxygenase-2 (COX-2) expression

• Modulates microglial phagocytic activity

Cytokine Production:

• IL-1β production and release

• TNF-α expression

• IL-6 and other pro-inflammatory mediators

• Chemokine secretion

Neuroinflammation Effects:

• Sustained neuroinflammation causes neuronal dysfunction

• Inflammatory cytokines promote tau pathology

• Creates feedback loop perpetuating neurodegeneration

Tau Pathology

p38 MAPK directly phosphorylates tau protein at multiple sites implicated in neurodegenerative disease^{4Tau phosphorylation by p38 MAPK2022 · J Biol Chem · PMID 35052561Open reference}:

Pathological Phosphorylation Sites:

• Serine-202 and Thr-205 (AT8 epitope)

• Serine-396

• Serine-404

• Serine-262 (found in early disease)

Consequences of Phosphorylation:

• Reduced microtubule binding

• Increased propensity for aggregation

• Impaired axonal transport

• Enhanced tau propagation between neurons

Kinase Cascade Activation:

• p38 MAPK activates GSK3β

• Cdk5 activation through upstream pathways

• Direct phosphorylation by p38 MAPK

Synaptic Dysfunction

p38 MAPK contributes to synaptic deficits in neurodegenerative disease^{5p38 MAPK and cognitive dysfunction2020 · Mol Neurobiol · PMID 32959093Open reference}:

Presynaptic Effects:

• Altered neurotransmitter release

• Impaired synaptic vesicle recycling

• Reduced synaptic plasticity

Postsynaptic Effects:

• NMDA receptor dysfunction

• Dendritic spine loss

• Impaired LTP (long-term potentiation)

Cognitive Decline

The cognitive impairment in PSP correlates with p38 MAPK-mediated processes:

• Hippocampal inflammation

• Synaptic loss in cortical regions

• Network connectivity disruption

• Executive dysfunction from frontal lobe involvement

p38 MAPK in Parkinson’s Disease and Related Disorders

Beyond PSP, p38 MAPK activation has been documented in Parkinson’s disease^{6p38 MAPK in Parkinson's disease2014 · Mov Disord · PMID 25209731Open reference}:

PD-Specific Considerations:

• Alpha-synuclein aggregation triggers p38 activation

• Mitochondrial dysfunction activates the pathway

• Microglial activation in substantia nigra

• Correlation with disease severity

Common Mechanisms:

• Neuroinflammation across synucleinopathies

• Tau co-pathology in some PD cases

• Shared inflammatory pathways

Rationale for PSP Specifically

PSP represents a compelling indication for p38 MAPK inhibition for several reasons^{7p38 MAPK inhibitors clinical development2021 · Pharmacol Res · PMID 33493738Open reference}:

1. Prominent Neuroinflammation: PSP brains show extensive microglial activation

2. Tau Pathology: Direct link between p38 activation and tau phosphorylation

3. Limited Treatment Options: No disease-modifying therapies exist

4. Well-Characterized Clinical Syndrome: Clear diagnostic criteria enable patient selection

5. Measurable Outcomes: Validated clinical rating scales (PSPRS) for endpoint assessment

Nefamapimod: Pharmacology

Chemical Properties

Nefamapimod (VX-745) is a selective, ATP-competitive inhibitor of p38α MAPK:

• IC50: Approximately 50 nM against p38α

• Selectivity: >100-fold selectivity over other kinases

• Molecular Weight: 379 Da

• Chemical Class: Pyridine-based small molecule

Pharmacokinetics

The pharmacokinetic profile of nefamapimod supports twice-daily dosing^{8Blood-brain barrier and p38 inhibitors2018 · PMID 29554550Open reference}:

• Oral Bioavailability: Moderate (~30-50%)

• Protein Binding: ~95% protein bound

• Half-life: 4-6 hours

• CNS Penetration: Demonstrated in preclinical models

• Metabolism: Hepatic, primarily through CYP450 enzymes

Mechanism of Action

Nefamapimod acts by inhibiting p38α MAPK catalytic activity:

1. ATP Competition: Binds to the ATP-binding pocket

2. Kinase Blockade: Prevents phosphorylation of downstream targets

3. Reduced Inflammatory Signaling: Decreased cytokine production

4. Tau Phosphorylation Reduction: Less tau phosphorylation at pathological sites

Preclinical Evidence

Preclinical studies with nefamapimod and related p38 inhibitors demonstrated:

• Reduced tau phosphorylation in animal models

• Decreased microglial activation

• Improved cognitive performance

• Neuroprotective effects in various models

Clinical Trial Design

Phase 2 Study Structure

The trial employed a rigorous randomized, double-blind, placebo-controlled design:

Study Phases:

1. Screening: 4-week period to confirm diagnosis

2. Treatment: 12 months of study drug or placebo

3. Follow-up: 4-week safety follow-up

Randomization:

• 2:1 randomization (active:placebo)

• Stratified by disease severity

• Age- and sex-balanced groups

Inclusion Criteria

Key Inclusion Criteria:

• Clinical diagnosis of probable PSP per NINDS-SPSP criteria

• PSP Rating Scale (PSPRS) score 20-70

• Age 40-85 years

• Disease duration 1-5 years

• Stable antiparkinsonian medications

Key Exclusion Criteria:

• Significant medical comorbidities

• Psychiatric disorders

• Prior participation in other clinical trials

• Contraindications to MRI

Endpoints

Primary Endpoint:

• Change in PSP Rating Scale (PSPRS) from baseline to 12 months

Secondary Endpoints:

• Cognitive function (MMSE, MoCA)

• Clinical Global Impression of Change (CGI-C)

• Quality of life measures

• MRI biomarkers

Exploratory Endpoints:

• CSF inflammatory markers

• Tau species in CSF

• Neuroimaging measures

Results and Findings

Safety Profile

Nefamapimod demonstrated an acceptable safety profile in the PSP patient population:

Common Adverse Events:

• Mild liver enzyme elevation (transient)

• Gastrointestinal symptoms (nausea, diarrhea)

• Headache

• Fatigue

Safety Conclusions:

• No serious drug-related adverse events

• Good tolerability at both dose levels

• No dose reduction due to tolerability issues

• Safety profile consistent with prior studies

Efficacy Outcomes

Primary Outcome:

• The primary efficacy endpoint (PSPRS change) did not meet statistical significance

• Trend toward slower progression in treatment group

• High placebo response observed

Secondary Analyses:

• Some positive trends in cognitive measures

• Post-hoc analysis suggested benefit in earlier disease stage patients

• Biomarker analysis showed target engagement

Biomarker Findings

Target Engagement:

• Reduced CSF inflammatory markers

• Evidence of p38 pathway modulation

• Dose-dependent biomarker effects

Imaging Findings:

• MRI volumetric measures in subset of patients

• Exploratory analysis of brain atrophy rates

Clinical Implications

Implications for PSP Treatment

The nefamapimod trial, while not meeting its primary endpoint, provides important insights:

1. p38 Target Validation: Further validates p38 MAPK as a relevant target

2. Patient Stratification: Suggests benefit may be limited to specific subpopulations

3. Trial Design: Informs future trials about placebo response in PSP

4. Biomarker Development: Demonstrates feasibility of biomarker endpoints

Comparison with Other Approaches

Future Directions

Based on trial results, several directions warrant exploration:

1. Earlier Intervention: Treat patients earlier in disease course

2. Combination Therapy: Combine with anti-tau approaches

3. Biomarker Selection: Use biomarker-positive patients

4. Next-Generation Inhibitors: More selective compounds

Neuroinflammation in PSP

Inflammatory Features

PSP demonstrates prominent neuroinflammatory changes^{9Neuroinflammation biomarkers in PSP2021 · J Neuroinflammation · PMID 34044785Open reference}:

Microglial Activation:

• Extensive activation in basal ganglia, brainstem

• Correlation with disease severity

• Pro-inflammatory phenotype predominates

Cytokine Profile:

• Elevated IL-1β, TNF-α in CSF

• Increased chemokine levels

• Relationship to tau pathology

Peripheral Immune:

• Systemic inflammation present

• Peripheral-CNS immune interaction

• Possible blood-brain barrier alterations

p38 MAPK as Therapeutic Target

The central role of p38 MAPK in neuroinflammation makes it an attractive target:

1. Central Coordinator: Regulates multiple inflammatory pathways

2. Brain-Penetrant: Can reach CNS target

3. Validated Preclinically: Strong preclinical rationale

4. Tau Link: Direct connection to tau pathology

Tau Biology in PSP

4R-Tauopathy

PSP is classified as a 4-repeat (4R) tauopathy, characterized by^{10Tauopathies classification2020 · Nat Rev Neurol · PMID 32015556Open reference}:

• Accumulation of tau isoforms with four microtubule-binding repeats

• Inclusion of straight filament tau aggregates

• Predominant involvement of subcortical structures

Tau Phosphorylation in PSP

Multiple kinases contribute to tau phosphorylation in PSP:

p38 MAPK Phosphorylation Sites:

• Ser202/Thr205 (AT8)

• Thr212/Ser214

• Ser396/Ser404

Other Kinases:

• GSK3β

• Cdk5

• JNK

• ERK1/2

Tau Propagation

The spread of tau pathology in PSP follows characteristic patterns^{2p38 MAPK in tauopathies2015 · J Neurochem · PMID 25645531Open reference}0:

1. Regional Spread: From brainstem to cortical regions

2. Network-Based: Along functional neural networks

3. Cell-to-Cell: Through synaptic connections

4. Mechanisms: Exosomal, synaptic, and extracellular mechanisms

p38 MAPK inhibition may reduce tau propagation by:

• Reducing tau phosphorylation

• Decreasing inflammatory-mediated spread

• Modulating cellular export mechanisms

PSP Clinical Features

Core Diagnostic Features

PSP-RS is characterized by^{2p38 MAPK in tauopathies2015 · J Neurochem · PMID 25645531Open reference}1:

Motor Features:

• Vertical supranuclear gaze palsy (particularly downward)

• Postural instability with falls within first year

• Akinesia and rigidity (axial predominant)

• Progressive gait disturbance

Cognitive Features:

• Executive dysfunction

• Bradyphrenia (slowed thinking)

• Behavioral changes

• Frontal lobe syndrome

Clinical Progression

Disease progression in PSP follows characteristic stages^{2p38 MAPK in tauopathies2015 · J Neurochem · PMID 25645531Open reference}2:

Early Stage (1-2 years):

• Primarily motor symptoms

• Often misdiagnosed as PD

• Mild disability

Middle Stage (2-4 years):

• Progressive gait disturbance

• Frequent falls

• Cognitive decline evident

• Speech and swallowing difficulties

Late Stage (4+ years):

• Severe disability

• Wheelchair dependence

• Severe dysphagia

• Cognitive impairment

Biomarkers in PSP

Diagnostic Biomarkers

Current research focuses on developing PSP biomarkers^{2p38 MAPK in tauopathies2015 · J Neurochem · PMID 25645531Open reference}3:

Imaging Biomarkers:

• MRI: Midbrain atrophy, “hummingbird sign”

• PET: Tau PET (limited for 4R tau)

• DTI: White matter integrity

Fluid Biomarkers:

• Neurofilament light chain (NfL)

• Total tau and phosphorylated tau

• Inflammatory markers

Prognostic Biomarkers

Biomarkers predicting progression:

• Baseline NfL levels

• Rate of brain atrophy

• Clinical phenotype

Safety Considerations

Drug-Drug Interactions

Nefamapimod may interact with:

• CYP450 substrates: Potential for drug interactions

• Anticoagulants: Monitor closely

• Other anti-inflammatory drugs: Additive effects

Special Populations

Renal Impairment:

• Limited data in severe renal impairment

• May require dose adjustment

Hepatic Impairment:

• Monitor liver function tests

• Avoid in severe hepatic impairment

Monitoring Requirements

During clinical trials:

• Regular liver function tests

• Vital signs monitoring

• ECG monitoring

• Adverse event collection

Comparison with Other p38 Inhibitors

Broader p38 Inhibitor Development

p38 MAPK inhibitors have been developed for various indications^{2p38 MAPK in tauopathies2015 · J Neurochem · PMID 25645531Open reference}4:

Lessons Learned

Clinical development of p38 inhibitors has revealed:

• Challenge of achieving efficacy in chronic CNS diseases

• Importance of early intervention

• Need for better patient selection

• Biomarker-driven development strategies

Future Directions

Combination Approaches

Rationale for combining p38 inhibitors with:

1. Anti-tau antibodies: Complementary mechanisms

2. Tau ASOs: Downstream and upstream targeting

3. Neurotrophic factors: Enhanced neuroprotection

Personalized Medicine

Future development may incorporate:

• Genetic stratification

• Biomarker-guided patient selection

• Phenotype-specific approaches

Next-Generation Compounds

Newer p38 inhibitors aim to improve:

• CNS penetration

• Selectivity (p38α only)

• Safety profile

• Dosing convenience

Cross-References

Related Disease Pages

• Progressive Supranuclear Palsy

• Corticobasal Syndrome

• 4R-Tauopathies

• Parkinson’s Disease

Related Mechanism Pages

• p38 MAPK Signaling Pathway

• Neuroinflammation in Neurodegeneration

• Tau Pathology Mechanisms

• Microglial Activation in Neurodegeneration

Related Clinical Trials

• ROCK Inhibitor Fasudil Trial

• GV1001 PSP Trial

• Tau PET Imaging Trial

• Lithium PSP Trial

Related Therapeutics

• p38 MAPK Inhibitors

• Anti-inflammatory Therapies

• Disease-Modifying Therapies

External Links

• ClinicalTrials.gov: NCT02444120

• PubMed: p38 MAPK inhibitors in neurodegeneration

• PSPRS Scale Information